Evidence map›Paper›PMID 31497203›Full record

ArticleAmerican journal of translational research2019

Overexpressed BSG related to the progression of lung adenocarcinoma with high-throughput data-mining, immunohistochemistry,

Wen-Ting Huang, Xia Yang, Rong-Quan He, Jie Ma, Xiao-Hua Hu, Wei-Jia Mo, Gang Chen

Open access · greenAbstract read
In one paragraph

Article in American journal of translational research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Wen-Ting HuangDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University Nanning, Guangxi Zhuang Autonomous Region, P. R. China.
Xia YangDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University Nanning, Guangxi Zhuang Autonomous Region, P. R. China.
Rong-Quan HeDepartment of Medical Oncology, First Affiliated Hospital of Guangxi Medical University Nanning, Guangxi Zhuang Autonomous Region, P. R. China.
Jie MaDepartment of Medical Oncology, First Affiliated Hospital of Guangxi Medical University Nanning, Guangxi Zhuang Autonomous Region, P. R. China.
Xiao-Hua HuDepartment of Medical Oncology, First Affiliated Hospital of Guangxi Medical University Nanning, Guangxi Zhuang Autonomous Region, P. R. China.
Wei-Jia MoDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University Nanning, Guangxi Zhuang Autonomous Region, P. R. China.
Gang ChenDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University Nanning, Guangxi Zhuang Autonomous Region, P. R. China.
Guangxi Medical University · CNFirst Affiliated Hospital of GuangXi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeLung adenocarcinoma (LUAD) of non-small cell lung cancer (NSCLC) is a highly prevalent cancer with high mortality. The gene basigin (BSG) is strongly expressed in certain tumors. This study investigated the expression level of BSG in LUAD and its role in the poor prognosis of LUAD.

methodsThe mRNA expression of BSG in LUAD was from GEO, Oncomine and TCGA database. Prognostic data were provided by SurvExpress. The expression of BSG protein was detected by immunohistochemistry (IHC). Cell function experiments of viability, proliferation and apoptosis assays were performed in A549. Clustering analysis of BSG co-expressed genes was generated by Gene Ontology (GO) Enrichment, KEGG pathway and protein-protein interaction (PPI) network.

resultsBSG mRNA level was significantly over-expressed in LUAD (pooled SMD = 0.564, 0.448-0.681, P<0.001). The analysis in SurvExpress revealed that high expression of BSG indicated significantly poor prognosis (pooled HR = 1.20, 1.10-1.30, P<0.0001). IHC assay also showed that BSG protein expression was significantly up-regulated in LUAD (P<0.001), and positive BSG expression was notably associated with higher pathology grade (P = 0.041) and lymphatic metastasis (P = 0.014). Moreover, BSG can enhance the viability and proliferation ability (both P<0.001) and weaken cell apoptosis (P<0.001) in A549. The most enriched GO terms in the co-expressed genes of BSG were translation related enrichment. The KEGG pathway showed that these genes were markedly involved in

conclusionUp-regulated BSG in LUAD is related to advanced progression and poor prognosis by influencing cell viability, proliferation and apoptosis. BSG could be a potential biomarker for the targeted therapy of LUAD.

Indexed as

apoptosisbasigin (BSG)bioinformatics analysisLung adenocarcinoma (LUAD)proliferationviability

Identifiers

PMID31497203
PMCPMC6731406
OpenAlexW2997937966

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.